Compare NAVI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | PSNL |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | United States |
| Employees | 670 | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.2M | 729.1M |
| IPO Year | N/A | 2019 |
| Metric | NAVI | PSNL |
|---|---|---|
| Price | $9.06 | $6.29 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.29 | ★ $12.20 |
| AVG Volume (30 Days) | 803.2K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.21% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $76.23 | $15.47 |
| Revenue Next Year | $15.73 | $39.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.80 | $3.20 |
| 52 Week High | $16.07 | $11.50 |
| Indicator | NAVI | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 63.25 | 41.11 |
| Support Level | $7.83 | $5.81 |
| Resistance Level | $13.34 | $6.94 |
| Average True Range (ATR) | 0.28 | 0.43 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 95.73 | 42.68 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.